Cargando…
Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer
Since its first approval by the FDA in 2017, tremendous progress has been made in chimeric antigen receptor (CAR) T cell therapy, the adoptive transfer of engineered, CAR-expressing T lymphocyte. CAR T cells are all composed of three main elements: an extracellular antigen-binding domain, an intrace...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670348/ https://www.ncbi.nlm.nih.gov/pubmed/37998743 http://dx.doi.org/10.3390/cimb45110566 |
_version_ | 1785139902691672064 |
---|---|
author | Ma, Hong Yun Das, Jeeban Prendergast, Conor De Jong, Dorine Braumuller, Brian Paily, Jacienta Huang, Sophia Liou, Connie Giarratana, Anna Hosseini, Mahdie Yeh, Randy Capaccione, Kathleen M. |
author_facet | Ma, Hong Yun Das, Jeeban Prendergast, Conor De Jong, Dorine Braumuller, Brian Paily, Jacienta Huang, Sophia Liou, Connie Giarratana, Anna Hosseini, Mahdie Yeh, Randy Capaccione, Kathleen M. |
author_sort | Ma, Hong Yun |
collection | PubMed |
description | Since its first approval by the FDA in 2017, tremendous progress has been made in chimeric antigen receptor (CAR) T cell therapy, the adoptive transfer of engineered, CAR-expressing T lymphocyte. CAR T cells are all composed of three main elements: an extracellular antigen-binding domain, an intracellular signaling domain responsible for T cell activation, and a hinge that joins these two domains. Continuous improvement has been made in CARs, now in their fifth generation, particularly in the intracellular signaling domain responsible for T cell activation. CAR T cell therapy has revolutionized the treatment of hematologic malignancies. Nonetheless, the use of CAR T cell therapy for solid tumors has not attained comparable levels of success. Here we review the challenges in achieving effective CAR T cell therapy in solid tumors, and emerging CAR T cells that have shown great promise for non-small cell lung cancer (NSCLC). A growing number of clinical trials have been conducted to study the effect of CAR T cell therapy on NSCLC, targeting different types of surface antigens. They include epidermal growth factor receptor (EGFR), mesothelin (MSLN), prostate stem cell antigen (PSCA), and mucin 1 (MUC1). Potential new targets such as erythropoietin-producing hepatocellular carcinoma A2 (EphA2), tissue factor (TF), and protein tyrosine kinase 7 (PTK7) are currently under investigation in clinical trials. The challenges in developing CAR T for NSCLC therapy and other approaches for enhancing CAR T efficacy are discussed. Finally, we provide our perspective on imaging CAR T cell action by reviewing the two main radionuclide-based CAR T cell imaging techniques, the direct labeling of CAR T cells or indirect labeling via a reporter gene. |
format | Online Article Text |
id | pubmed-10670348 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106703482023-11-12 Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer Ma, Hong Yun Das, Jeeban Prendergast, Conor De Jong, Dorine Braumuller, Brian Paily, Jacienta Huang, Sophia Liou, Connie Giarratana, Anna Hosseini, Mahdie Yeh, Randy Capaccione, Kathleen M. Curr Issues Mol Biol Review Since its first approval by the FDA in 2017, tremendous progress has been made in chimeric antigen receptor (CAR) T cell therapy, the adoptive transfer of engineered, CAR-expressing T lymphocyte. CAR T cells are all composed of three main elements: an extracellular antigen-binding domain, an intracellular signaling domain responsible for T cell activation, and a hinge that joins these two domains. Continuous improvement has been made in CARs, now in their fifth generation, particularly in the intracellular signaling domain responsible for T cell activation. CAR T cell therapy has revolutionized the treatment of hematologic malignancies. Nonetheless, the use of CAR T cell therapy for solid tumors has not attained comparable levels of success. Here we review the challenges in achieving effective CAR T cell therapy in solid tumors, and emerging CAR T cells that have shown great promise for non-small cell lung cancer (NSCLC). A growing number of clinical trials have been conducted to study the effect of CAR T cell therapy on NSCLC, targeting different types of surface antigens. They include epidermal growth factor receptor (EGFR), mesothelin (MSLN), prostate stem cell antigen (PSCA), and mucin 1 (MUC1). Potential new targets such as erythropoietin-producing hepatocellular carcinoma A2 (EphA2), tissue factor (TF), and protein tyrosine kinase 7 (PTK7) are currently under investigation in clinical trials. The challenges in developing CAR T for NSCLC therapy and other approaches for enhancing CAR T efficacy are discussed. Finally, we provide our perspective on imaging CAR T cell action by reviewing the two main radionuclide-based CAR T cell imaging techniques, the direct labeling of CAR T cells or indirect labeling via a reporter gene. MDPI 2023-11-12 /pmc/articles/PMC10670348/ /pubmed/37998743 http://dx.doi.org/10.3390/cimb45110566 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ma, Hong Yun Das, Jeeban Prendergast, Conor De Jong, Dorine Braumuller, Brian Paily, Jacienta Huang, Sophia Liou, Connie Giarratana, Anna Hosseini, Mahdie Yeh, Randy Capaccione, Kathleen M. Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer |
title | Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer |
title_full | Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer |
title_fullStr | Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer |
title_full_unstemmed | Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer |
title_short | Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer |
title_sort | advances in car t cell therapy for non-small cell lung cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670348/ https://www.ncbi.nlm.nih.gov/pubmed/37998743 http://dx.doi.org/10.3390/cimb45110566 |
work_keys_str_mv | AT mahongyun advancesincartcelltherapyfornonsmallcelllungcancer AT dasjeeban advancesincartcelltherapyfornonsmallcelllungcancer AT prendergastconor advancesincartcelltherapyfornonsmallcelllungcancer AT dejongdorine advancesincartcelltherapyfornonsmallcelllungcancer AT braumullerbrian advancesincartcelltherapyfornonsmallcelllungcancer AT pailyjacienta advancesincartcelltherapyfornonsmallcelllungcancer AT huangsophia advancesincartcelltherapyfornonsmallcelllungcancer AT liouconnie advancesincartcelltherapyfornonsmallcelllungcancer AT giarratanaanna advancesincartcelltherapyfornonsmallcelllungcancer AT hosseinimahdie advancesincartcelltherapyfornonsmallcelllungcancer AT yehrandy advancesincartcelltherapyfornonsmallcelllungcancer AT capaccionekathleenm advancesincartcelltherapyfornonsmallcelllungcancer |